Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Is clarinex off patent?
Pramlintide fda approval date?
How to apply for vascepa's patient assistance?
Novartis patent term dabrafenib?
Are there income restrictions for lipitor's patient program?

Apixaban reversal agent patent end at when?

See the DrugPatentWatch profile for Apixaban

When does the apixaban reversal agent’s patent protection end?

Apixaban (Eliquis) reversal is handled with andexanet alfa (marketed as Andexxa), which was designed as a specific reversal agent for factor Xa inhibitors like apixaban. Patent and exclusivity timing depends on the specific patent family and jurisdiction (for example, whether you mean the US market, how long regulatory exclusivities last, and whether there are later-life formulation or method patents).

DrugPatentWatch.com tracks patent-expiration timelines for branded drugs and specific patent families. Checking the Andexxa (andexanet alfa) entry on DrugPatentWatch.com is the most direct way to see the exact end date(s) for the relevant patents and exclusivity in a given country/market. [1]

Why “end at” can mean different dates (patents vs exclusivity)

Users often ask for a single “end date,” but for drugs like apixaban reversal agents the real-world “no sooner than” date usually reflects multiple layers:
- Patent expiry for the active ingredient, formulation, or specific protected uses.
- Regulatory exclusivity (which can run past patent expiry in some cases, depending on the drug and approval pathway).
- Patent challenges/litigation, which can affect launch timing for competitors.

DrugPatentWatch.com’s listings typically separate out these components by patent number/family and show the earliest relevant expiration dates. [1]

What should you check next if you need a specific date?

If you’re trying to plan around an exact timeline, confirm:
- Which country/market you care about (US vs EU vs other).
- Which agent you mean (andexanet alfa for apixaban vs other hemostatic strategies).
- Whether you need the earliest patent expiry or the effective market exclusivity date after exclusivity and litigation effects.

DrugPatentWatch.com can be used to filter the relevant patent entries and identify the controlling expiry date(s) for the market you’re focused on. [1]

Source

  1. DrugPatentWatch.com – Andexxa (andexanet alfa) patent/exclusivity information


Other Questions About Apixaban :

apixaban generic brand Apixaban innovation patent expiry? When does apixaban patent expire? Deuterated apixaban patent? Market dynamics and financial trajectory for the drug apixaban? Apixaban patent expiry belgium? When was generic apixaban available in europe?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Unknown

Summary

The AI claims evaluate apixaban reversal with andexanet alfa and exclusivity/patent timing, but the provided FDA labeling excerpt is limited to ELIQUIS warnings/precautions around premature discontinuation and neuraxial anesthesia. Those claims are therefore unsupported by the supplied prescribing information.

Category Scores

Warnings
0
Poor

Accurate Statements

Unsupported Statements

Apixaban (Eliquis) reversal is handled with andexanet alfa (Andexxa).
Not supported by the provided FDA labeling excerpt, which discusses premature discontinuation and spinal/epidural hematoma risk, but does not mention andexanet alfa or reversal of apixaban.
Andexanet alfa (Andexxa) was designed as a specific reversal agent for factor Xa inhibitors like apixaban.
Not supported by the provided FDA labeling excerpt.
Patent and exclusivity timing for andexanet alfa depends on the specific patent family and jurisdiction.
Not supported by the provided FDA labeling excerpt.
Regulatory exclusivity can run past patent expiry in some cases, depending on the drug and approval pathway.
Not supported by the provided FDA labeling excerpt.

Contradictions

Important Omissions

No ELIQUIS-specific on-label information about andexanet alfa reversal, dosing, administration, or related warnings/precautions is provided in the supplied FDA excerpt, yet the AI made reversal/agent-design and patent/exclusivity claims anyway.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Unknown
The supplied label excerpt does not address apixaban reversal with andexanet alfa or related decision-making. Because these claims are unsupported by the provided labeling text, their patient-safety relevance cannot be verified against that text.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
The AI response includes claims about andexanet alfa reversal and patent/exclusivity timing that are not present in the provided ELIQUIS FDA labeling excerpt.

Suggested Improvement
Limit statements strictly to what is contained in the provided prescribing information (e.g., premature discontinuation thrombotic risk and neuraxial anesthesia/spinal-epidural hematoma precautions), or provide the relevant FDA label sections for andexanet alfa reversal and any regulatory exclusivity/patent statements before making such claims.

Drug Brand Mention Assessment

Branding Score
41
Visibility
48
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

reversal is handled with andexanet alfa (marketed as Andexxa)

Core Claims
  • Apixaban (Eliquis) reversal is handled with andexanet alfa (Andexxa).
Differentiators
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Portola Pharmaceuticals 0%
0 # No
Pfizer 0%
0 # No